Clinical Trial Update: Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A Phase 1 repeated-dose study in Japanese patients with Type 1 diabetes evaluated a new insulin glargine formulation alongside Lantus on 24-hour glucose profile…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (new formulation) (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED